Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies
Kristian Reich, Kim Papp, April W. Armstrong, et al.
British Journal of Dermatology (2018) Vol. 180, Iss. 5, pp. 1039-1049
Closed Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich, April W. Armstrong, Richard Langley, et al.
The Lancet (2019) Vol. 394, Iss. 10201, pp. 831-839
Closed Access | Times Cited: 302
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease, Proton Rahman, Alice B. Gottlieb, et al.
The Lancet (2020) Vol. 395, Iss. 10230, pp. 1126-1136
Open Access | Times Cited: 278
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke, et al.
The Lancet (2020) Vol. 395, Iss. 10230, pp. 1115-1125
Open Access | Times Cited: 263
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2020)
Open Access | Times Cited: 164
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2021) Vol. 2021, Iss. 12
Open Access | Times Cited: 135
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 109
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, Robin Guelimi, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 92
Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 17
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
L. Sawyer, K Malottki, Celia Sabry-Grant, et al.
PLoS ONE (2019) Vol. 14, Iss. 8, pp. e0220868-e0220868
Open Access | Times Cited: 139
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Miguel Nogueira, L. Puig, Tiago Torres
Drugs (2020) Vol. 80, Iss. 4, pp. 341-352
Closed Access | Times Cited: 137
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
Kristian Reich, C.E.M. Griffiths, Kenneth B. Gordon, et al.
Journal of the American Academy of Dermatology (2019) Vol. 82, Iss. 4, pp. 936-945
Open Access | Times Cited: 78
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
Ahmed Almradi, Jurij Hanžel, Rocío Sedaño, et al.
BioDrugs (2020) Vol. 34, Iss. 6, pp. 713-721
Closed Access | Times Cited: 76
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
Kilian Eyerich, Peter Weisenseel, Andreas Pinter, et al.
BMJ Open (2021) Vol. 11, Iss. 9, pp. e049822-e049822
Open Access | Times Cited: 59
Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
Andrew Blauvelt, Andrea Chiricozzi, Benjamin D. Ehst, et al.
Advances in Therapy (2023) Vol. 40, Iss. 8, pp. 3410-3433
Open Access | Times Cited: 28
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study
Koen Dudink, Klasiena Bouwman, Yanqing Chen, et al.
British Journal of Dermatology (2023) Vol. 188, Iss. 5, pp. 601-609
Open Access | Times Cited: 27
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence
Xiaoying Sun, Ziyang Cui, Qingyun Wang, et al.
Autoimmunity Reviews (2024) Vol. 23, Iss. 4, pp. 103530-103530
Closed Access | Times Cited: 11
Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
Paras Karmacharya, Alexis Ogdie, Lihi Eder
Therapeutic Advances in Musculoskeletal Disease (2021) Vol. 13
Open Access | Times Cited: 54
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Andrew Blauvelt, Tsen‐Fang Tsai, Richard Langley, et al.
Journal of the American Academy of Dermatology (2021) Vol. 86, Iss. 4, pp. 827-834
Closed Access | Times Cited: 44
Anti-interleukin-23 agents for the treatment of ulcerative colitis
Jurij Hanžel, Geert R. D’Haens
Expert Opinion on Biological Therapy (2019) Vol. 20, Iss. 4, pp. 399-406
Open Access | Times Cited: 53
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study
Laura K. Ferris, Elyssa Ott, Jingzhi Jiang, et al.
Journal of Dermatological Treatment (2019) Vol. 31, Iss. 2, pp. 152-159
Open Access | Times Cited: 46
Guselkumab for the treatment of psoriasis – evidence to date
Miguel Nogueira, Tiago Torres
Drugs in Context (2019) Vol. 8, pp. 1-11
Open Access | Times Cited: 45
Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial
Sascha Gerdes, Beate Bräu, Matthias Hoffmann, et al.
The Journal of Dermatology (2021) Vol. 48, Iss. 12, pp. 1854-1862
Open Access | Times Cited: 37
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks
Marco Galluzzo, Lorenzo Marcelli, Laura Vellucci, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 4, pp. 371-381
Open Access | Times Cited: 14
State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis
Paolo Gisondi, Davide Geat, Miriam Pizzolato, et al.
Current Opinion in Pharmacology (2019) Vol. 46, pp. 90-99
Closed Access | Times Cited: 40
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
C.E.M. Griffiths, Kim Papp, Michael Song, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 2, pp. 848-856
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top